Fortrea faces a tough squeeze as stricter rules, drug pricing pressure, and bigger clients push harder on what they’re willing to pay, while the company also risks falling behind on modern trial technology. But if it cuts costs, upgrades its tools, and keeps winning work from large drugmakers, it could still improve how efficiently it runs and strengthen results over time.Read more
Fortrea helps drug and medical device makers run clinical trials, and steady healthcare demand could lift the business as the market steadies. But heavy reliance on a handful of big customers and tough competition may limit how quickly results improve.Read more
Fortrea is trying to turn clinical research into a leaner, more digital business, using automation and new software to cut waste and win higher‑value work as drug trials grow more complex. But a heavy reliance on a handful of big customers and intense price competition could derail the turnaround if new projects don’t come in as expected.Read more
No trending discussion available.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
